In another study, a triple-membrane hybrid composed of erythrocytes, U251 glioma cells, and macrophages integrated key membrane markers from each source—CD47 for immune evasion, CD44 for glioma targeting and BBB transport, and CD86 for immune modulation. This evidence concerns the gene CD44 and central nervous system cancer.